Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 17Stomach Neoplasms 5Rectal Neoplasms 2Colonic Neoplasms 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1TAS 102 1Sarcoma 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Metastasis Colorectal Cancer 1Locally Advanced Rectal Cancer 1HER2-positive Gastric Cancer 1Fruquintinib 1Esophageal Squamous Cell Carcinoma 1Colorectal Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Biliary Tract Adenocarcinoma 1Advanced Pancreatic Carcinoma 1

Interventions

HMPL-013 2toripalimab 1tislelizumab 1sintilimab 1regorafenib 1raltitrexed 1pembrolizumab 1camrelizumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Advanced Colorectal Carcinoma × HMPL-013 × Clear all
NCT05406206 2022-06-06

Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

Peking University Cancer Hospital & Institute

Phase 2 Unknown
27 enrolled
Gastrointestinal

Advanced Colorectal Carcinoma

NCT04582981 2021-10-26

Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer

Fudan University

Phase 2 Unknown
136 enrolled
Gastrointestinal

Advanced Colorectal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡